Skip to main content

Cannabis Use Not Associated With Elevated Risk Of Secondary Cancer Per Study

It is estimated that roughly 4% of all cancer patients suffer from head and/or neck cancer. As with any form of cancer, head and neck cancer are absolutely awful for anyone to have to battle.

The results of a recent cannabis study provide some encouraging news for those that suffer from those particular forms of cancer. Below is more information about it via a news release from our friends at NORML:

Patients with head and neck cancers who possess a history of cannabis use are not at an increased risk of developing a secondary cancer diagnosis, according to data published in the journal Cureus.

A team of researchers affiliated with McMaster University, the University of Toronto, and the University of British Columbia assessed the association between cannabis smoking and the risk of developing a second primary squamous cell carcinoma in patients previously diagnosed with head and neck cancer.

Investigators reported that those who consumed cannabis “showed lower odds of developing SPC” compared to non-users.

“These results suggest that cannabis behaves differently than tobacco smoking,” they concluded. “Our results are consistent with the theory that cannabis is not carcinogenic and hence would not follow patterns of field cancerization.”

The study’s findings are consistent with those of prior papers concluding that cannabis smoke and tobacco smoke are not equally carcinogenic and that marijuana smoke exposure is not associated with many types of tobacco-related diseases, such as lung cancer and COPD.

Full text of the study, “Rate of second primary head and neck cancer with cannabis use,” appears in Cureus. Additional information is available from the NORML white paper, “All Smoke Is Not Created Equal.”

Tel Aviv Stock Exchange Now Has A Cannabis Index

For many years investing in the emerging cannabis industry was a very tricky thing for many reasons, not the least of which was that the cannabis industry was operating in a legal ‘grey area.’

Places such as Amsterdam and British Columbia were home to cannabis-based businesses like cannabis cafes that were ‘tolerated’ by local authorities.

Arguably the biggest evolution in the cannabis industry came in 1996 when voters in California legalized cannabis for medical use, which resulted in the exponential growth of medical cannabis dispensaries and cultivation operations throughout California.

For many years cannabis investments operated in those types of markets, and/or revolved around ancillary cannabis inventions and ideas. The reward was significant, however, so were the risks.

Zoom forward to today and there are far more options for investing in the emerging cannabis industry, including and especially cannabis stock investment options.

Multiple stock exchanges now allow cannabis company listings, including in Israel. Per The Jerusalem Post:

The Tel Aviv Stock Exchange launched on Monday a new index for nine medical cannabis companies in an effort to boost trade in the burgeoning, yet not quite mature, sector.

The new index includes nine companies that are “primarily engaged in the fields of research, cultivation, sale or production and marketing of medical cannabis products”, the stock exchange said.

Israel is rapidly taking its rightful spot as an international cannabis leader. The Middle Eastern nation has long been an international leader for cannabis research, but the country’s medical cannabis program was limited for many years.

Now Israel not only has plans to become a major exporter of cannabis but also has plans to legalize cannabis for adult-use next year. If you are looking to invest in cannabis, you should definitely keep an eye on Israel to see how things develop.

Cannabis Legalization Is A Political Issue Most Americans Agree On

To say that the United States is divided when it comes to politics is a massive understatement. One could easily argue that the political climate in the U.S is more polarized than it has been in well over 100 years.

However, at a time when most U.S. voters do not seem to agree on almost anything, there is one issue that has support from all over the political spectrum, and that support continues to increase with every passing year.

That political issue is cannabis legalization. Support for cannabis legalization is at an all-time high in the United States, no pun intended, and that is reflected in the results of a new poll. Below is a news release about it from our friends at NORML:

Majorities of Democratic, Republican, and Independent voters endorse legalizing the use of marijuana for adults and this support is growing, according to polling data compiled by the firms FM3 Research and Fabrizio, Lee & Associates and first reported by MarijuanaMoment.net.

Pollsters surveyed voters in Arizona, Montana, New Jersey, and South Dakota. A majority of voters in each of the four states decided in favor of adult-use legalization ballot measures on Election Day.

Sixty-eight percent of those surveyed – including 85 percent of Democrats, 66 percent of Independents, and 53 percent of Republicans – support legalizing marijuana. That finding is consistent with other nationwide polls.

More than one-quarter of respondents (27 percent) – including 33 percent of Democrats, 35 percent of Independents, and 23 percent of Republicans – said that their views have become more favorable toward legalization in recent years. Sixty-five percent of respondents agreed with the statement, “Legalizing adult use of marijuana is a non-partisan issue that both liberal and conservative voters can get behind.”

Eighty-one percent of respondents agreed that the federal government should not interfere with state laws legalizing marijuana use.

Pollsters concluded: “The results carry important insights, especially for Republican elected officials” who often “cast cannabis legalization as a partisan wedge issue.” This position, pollsters acknowledged, is growing “increasingly untenable” with Republican voters.

Cannabis And Privacy On Collision Course In The UK?

As Brexit confuses matters, and the NHS considers a patient registry, what is on the agenda for the protection of cannabis patient rights?

The NHS has now announced a new cannabis patient database, even as the island sets sail for a general regulatory free environment in the aftermath of whatever Brexit will be. Beyond tens of miles of lorries on either side of the Channel, however, what does this mean for patient privacy generally in the UK? Will it merely follow the path of North American users, who are also caught up in the conversation about big tech and privacy rights?

Privacy and cannabis use has been a big issue just about everywhere, particularly since 2014 when Canada and the United States both began to move towards recreational reform. So far, at least in North America, the problems remain contentious, widely undressed, and as a result, in limbo, for now.

Europe is another matter. The medical market here has matured along with a renewed interest in both privacy rights and online shopping. In Europe proper, as a result, GDPR, or general data protection legislation is a big deterrent to getting it wrong.

Such trends are also unlikely to go away as Europe in particular, finally begins to challenge American big Tech and as of next year.

Even the newly brexited island off the west coast of the Channel has some kind of GDPR protection also known as the United Kingdom will be affected.

So far, beyond the proposed NHS database, a non-profit research organization is also gathering data under the rubric of ProjectTwenty21, which presumably will also then share such data with the companies that sponsor it.

It might be a “dodge,” but in a country with many issues about reconstituting itself as an independent actor, and further one after Covid, everyone is looking for a new way of doing things.

The question remains, however, whether the new solutions will be any less problematic as the old ones?

Hemp Advertising Does Not Obviate The Issues

As much as the recent European Commission decision on the regulation and advertising of hemp creates many opportunities for both brands and canna media, in particular, many jungles remain. This includes understanding how a recreational cannabis market is different from a medical one. In an environment where most patients are still caught in the black market and are unable to afford any legitimate channel for their drug, this entire debate means nothing.

Who Should Have Access To Cannabis Patient Databases?

The discussion about access to new drug and patient databases has been in the room since the establishment of the pharmaceutical industry in the last century. However, in a world where social media and marketing have redefined whole industries, starting with advertising itself, there are no easy answers. And while the cannabis industry in the UK may feel they have just been given a pass while Europe shoulders on with more challenges to big tech (far from cannabinoids), it will not be that easy, even next year.

Be sure to attend the International Cannabis Business Conference when it returns to Europe in 2021.

Pandemics, Mergers And 2020 – Oh, My, Goodbye!

A strange year has wound up with a whimper rather than a bang as two of the largest Canadian public cannabis companies merge in a cashless transaction and one of them adds dronabinol to its product roster.

It is unlikely that the memory of 2020 will recede any time soon. The Pandemic created new opportunities, however, for many in the cannabis industry who could brave the course of events, starting in the United States and Canada. Dispensaries were labeled “essential” and being allowed to stay open (although the cannabis club world was thrown into disarray in places like Spain) meant a vital difference to many in the industry.

Further afield, and at the end of the year, global and regional regulatory mandates also moved the needle forward, even if in some instances incrementally. The UN vote to move cannabis out of Schedule IV is a mere political nod to the obvious without shaking any more boats. The reality is that Schedule I designation means that individual countries and regions beyond that, will now have to shoulder through all the messy details of both legalization and incorporation of the drug into other regulatory buckets and business environments. The EC vote on hemp, namely that CBD is not a narcotic was far more meaningful, along with the ability to now market hemp products openly like any other good. Look for European innovation on that front as a result, and as of early next year. That includes new media, new technology, and of course a new debate about the entire ball of wax as Luxembourg finally begins its recreational market and Holland ushers in a more regulated industry.

That said, it is also unavoidable to note that 2020 was certainly not a good year for big pot, no matter the temporary bounce in stock prices for a few. Delays in the production schedule for new facilities in Germany caused by Covid have clearly had an effect on the remaining two bid winners. Wayland, it should be remembered, was the only bid winner which had actually spent money on production facilities that became operational before the awarding of the bid. They merged with ICC right as the bid was awarded, and the bid production contracts have ended up with Demecan. Last week, it emerged that Aphria was merging with Tilray in a similar fashion. Aurora has also struggled, closing a huge cultivation space in Canada.

The ghosts of the first German tender are still in the room even as the entire continent struggles with how to classify the plant, and now, in the aftermath of Covid, economic redevelopment.

One thing is for sure. Cannabis is going to be on the drawing boards of every country as the world rebuilds from Covid. And if that is not the best, most catchy holiday season’s greetings, it doesn’t sound all that bad at this point. There is a light, indeed at the end of a very long tunnel.

Be sure to book your tickets to the International Cannabis Business Conference when it returns to Europe in 2021!

Mexico Extends Cannabis Legalization Deadline, Again

In late 2018 Mexico made international headlines and turned heads in the global cannabis community when Mexico’s Supreme Court ruled that cannabis prohibition was unconstitutional.

When the Supreme Court rendered the decision, it mandated that lawmakers in Mexico pass a cannabis legalization measure to codify the decision and work to implement the new law.

Originally, the Court issued a one-year deadline. Unfortunately, as the one-year deadline approached, it was obvious that lawmakers in Mexico would not be able to comply with the mandate.

Lawmakers in Mexico were granted a new deadline, April 2020, and that extension was also not met due to COVID. Yet another deadline was granted, and yet another time the deadline could not be met, as reported by Reuters:

Mexico’s President Andres Manuel Lopez Obrador on Tuesday blamed small draft errors for a delay in approving a new law that would legalize cannabis and effectively create one of the world’s largest weed markets.

The bill was due to be approved by Dec. 15, but it has been delayed to next year, with the Supreme Court setting a new deadline of April 30 for the law to be passed, according to local media.

Lopez Obrador said legislators requested a delay as time had run out before the current session in Congress ended this month, meaning there was not enough time to review the bill.

The legalization saga in Mexico continues. Will the latest deadline be met, or will another extension be requested? Only time will tell.

Lawmakers in Mexico have expressed optimism on several occasions just for that optimism to deflate. Eventually, Mexico will push the effort over the top, but it is anyone’s guess when that will be. Hopefully, it is sooner rather than later.

Ready, Set, Thai Canna Tour?

Thailand plans a tour to educate locals about medical cannabis. Fully-fledged production is the goal, but will this lead to other things – like organized canna tourism for foreigners?

Tourism and Sports Minister Phiphat Ratchakitprakam has announced that the federal agency is backing a formal medical marijuana tour. The idea is to increase awareness of the medical efficacy of cannabis among locals who are interested in venturing into cultivation.

According to the Bankok Post, 8 provinces have plantations that will serve as part of the tour, and anyone can purchase a tour package, which includes visiting the farms, and education about how to grow the plant commercially.

The Thai government is also moving fairly quickly to implement not only reforms but the infrastructure necessary to nurture a cannabis industry. In August of this year, the Thai cabinet approved an amendment to the country’s Narcotic Act to allow private medical practitioners, traditional healers, and farmers to grow cannabis for medical treatment. Just two years ago on Christmas Day, the government approved the medical use of cannabis, becoming the first country in Southeast Asia to legalize cannabis for medical purposes.

The Implications Elsewhere

There are still few governments that seem to be as open to creating a national economy for locals as the way the Thai government appears to be going about legalization. In most countries, starting with Europe but also including Australia, New Zealand, and South Africa, the entire process of cannabis cultivation has been limited to existing farmers or cultivators who could raise significant amounts of cash to begin construction of specialized grow facilities and a supply chain that would pass medical muster.

The Thai government, however, appears to be taking a vastly different tact. Namely, making sure that national farmers are given the first opportunity to enter the market and keep control of a commodity that so far has mostly been dominated by those with deep pockets and from elsewhere.

This attempt to keep the cannabis market in local hands may well still traverse the path seen elsewhere – namely selling itself to foreign investors to raise capital for a fully licensed supply chain. However, it also may not. There is considerable backlash growing against the Canadian public industry, in particular. And more and more countries are beginning to understand that keeping cannabis production local is a vital element of national security, just like the ability to grow other food and plants for medicine.

Indeed, the Thai experiment may yet produce its own exotic strain of reform in the coming years that may well leapfrog its way into other national discussions.

Make sure to book your tickets to the International Cannabis Business Conference when it returns to Europe in 2021.

Switzerland Clarifies Rules For Dispensing Medical Cannabis

Medical cannabis treatment will no longer require a special permit in Switzerland, although it is unclear whether health insurance will cover it.

Until now, doctors in Switzerland had to obtain a special exemption permit from the Federal Office of Public Health (FOPH) to issue prescriptions for cannabis. Last year about 3,000 permits were issued. Those days have now come to a close. According to the Federal Council, this procedure is no longer appropriate, given the rising numbers of patients. Namely, it makes treatment more difficult and delays its start. As a result, the Grand Chamber of Parliament is proposing lifting the ban on the same in the Narcotics Act.

The new law stipulates that cannabis therapy should be a matter only between doctor and patient. The government will monitor prescriptions, however, and practitioners will have to submit data on the same to the government.

Insurance coverage in Switzerland has still not been decided. So for now, patients must still cover the cost of their medications.

Will Switzerland Go The Way of Holland?

The ability to prescribe cannabis directly is one of the biggest things that began to move the German market forward – but so was the ability to obtain coverage by insurers – at least in theory. There have been multiple issues between legislation and reality, to the point that patients continue to sue for access. Indeed as of October, a new ruling by the Social Benefits court ruled that the regional approvers, called the MDK, cannot interfere in the relationship between doctor and patient when it comes to prescription for the longer term.

However, trial programs, such as the ones that exist in Luxembourg, Germany, and to some extent Denmark, are also in danger of literally being overrun by the recreational discussion now also in the room. It is far easier for patients to obtain their cannabis, barring the cost, if they do not have to interact with the medical system. Indeed, that is the decision Holland made just as Germany was making the move to incorporate coverage under the formal medical infrastructure that includes insurers and regional approvers.

Given the slow trajectory Switzerland has taken so far, despite the popularity of the non-medical “Cannabis Lite” it is not unreasonable to assume that they might too, decide that cannabis is an expensive and unnecessary medicine and leave patients to their own devices.

The jury, if not report, is still out.

Make sure to book your tickets to the International Cannabis Business Conference when it returns to Europe in 2021

New Book On German Cannabis Cultivation Tender Pulls No Punches

Marguerite Arnold goes behind the scenes of the exploding German cannabis market at a critical time – the first cultivation bid.

In this fascinating, hard to put down, and perfect digital Christmas stocking stuffer, Marguerite Arnold, among other things, a veteran “foreign” cannabis correspondent, tells a story that is absolutely an insider’s account of the holy mess made by authorities and companies alike as everyone scrambled to be first in this foreign green gold rush and as modern reform came to Europe.

This is, at heart, the story of the first federal cultivation bid for the cultivation and distribution of medical cannabis in Germany – but the story stretches far beyond just that.

Green II: Spreading Like Kudzu is a lot of things – but here are a few ways to describe it – starting with being the first business book about the German and European cannabis industry. It is hard to categorize the Ebook generally beyond that – except for the fact that it is one of the few so far to cover it in ways that are both professional snapshot and intriguing for other reasons (even for people with no idea what reverse mergers or cannabinoids are). As such it is part a must-read for anyone considering entering the European if not global cannabis trade (and Arnold’s explanations of the securities exploits of the Canadian public companies is a priceless, well-documented epic, worth just the price of the book alone).  So is her easy-to-read description of some of the bigger issues about regulation and certification.

It is well-written and sourced, authoritative and often funny. As such it will also be a great introduction to the entire cannabis discussion for any relatives or colleagues with questions. Not to mention aspiring canna MBAs with international inclinations. Indeed, one of the more intriguing parts of the book is also the preface where Arnold briefly describes her own cannabis themed journeys – including winning a German Supreme Court case that is already considered one of the most important “Right To Return” reforms to domestic immigration law since WWII.

But Green is also part travelogue and time travel trip too. Arnold’s visit to a Polish cannabis safe house is a touching if not fascinating reflection of how the “movement” in Europe is still reminiscent of the scene in California, New York and Washington DC in the 80’s and 90’s – no matter how removed in geography and time. Her discussion of the politics and socioeconomic questions are also interesting, particularly coming at a time of such massive change for Germany and Europe as well as the Brexiting UK far beyond just cannabis. She also profiles leading experts, such as Dr. Franjo Grotenhermen, Raphael Mechoulam, and, from the private sector, international cannapreneurs she obviously encounters on a regular basis.

Of course it is hard to be entirely objective. She also gives the International Cannabis Business Conference kudos as the most important business conference on the planet!

Here is a brief excerpt from Chapter 4 about the conference itself:

The Cannes of Cannabis

On the first day of April, Alex Rogers strode onto a stage at a central Berlin conference hotel just two blocks from the Spree River that meanders through the middle of the city. He was here to open the third annual International Cannabis Business Conference. In front of him were close to a thousand people – all working in, in some capacity, the international legal cannabis industry from all over the world. Literally. 

The International Cannabis Business Conference is a professional conference so there are not many “wanna-bes” who show up. People who come are invested in a serious way, no matter how big or small the amount, in an industry they want a ground floor entry to as the entire conversation continues to get disruptive.

Even those who deliberately stayed home this year sent a message – namely that they could not be there without being put on the spot about burning questions only a closed and still privileged few really were in the know about. Even on that score – namely those with answers about the bid, could not defer the growing rumors, certainly by the second day of the International Cannabis Business Conference, that news about the resolution of the tender was in the air a full week before the second lawsuit against the bid in Düsseldorf had even been heard.

For this reason, including hoping to gain an inside tip on who won and those lining up for sales generated by it by this year, the International Cannabis Business Conference had become a well attended, avidly anticipated conference if not annual event. In the process, the conference has also served to create a unification point for not only a German but budding and nascent cross-European and indeed completely international industry to meet, make friends and do business. Especially as, even in the German market, Berlin was not the de facto “center” of the industry anymore. By this time, major firms and budding distributors were speckled all over the German map (including Cologne, Frankfurt, Munich and even the Ruhrgebeit’s Dortmund).

Attendees ran the gamut of firms too. Sure the big “name” Canadian producers were here. This year, however, as in years past, they also shared the conference with smaller firms now seeing Europe as a clear entry point on their roadmaps. Israelis were here in force, including vape makers Kanabo, unashamedly going head-to-head with industry standard if not fave, the German Storz and Bickel.

Yet everyone here, no matter whether they took a straßenbahn (street car) or hopped several international time zones to attend, had one clear mission: plotting the details if not logistics of their European landing. 

Looking out across this sea of faces on the first day of the International Cannabis Business Conference this year, it was hard for Rogers to contain his pride if not his excitement. This was going to be the best year ever. Attendance was through the roof and the conference sported a record number of sponsored booths and tables.

“Welcome to Berlin and the International Cannabis Business Conference, y’all,” he said, a grin splitting his face from ear to ear. 

“My sister went to Princeton, ” Rogers announced, and then paused, knowing, from experience what the next reaction from the crowd would be.  “And I went to prison.” He couldn’t help laughing himself. There is a happy ending to this story. Rogers is living it large these days.

The attendees’ laughter rippled through the assembled throng like a gurgling brook on a sunny day because it’s a crowd-pleaser every time. Including because, in too many parts of the world, being in the “biz” means taking risks and facing down dangers that seem unimaginable to most people, still.

This opening, understandably, is one of Rogers’ favorite lines, but it also sums up a section of his career path well. It may be alliterative and kind of humorous too, but it also has the poignancy of a man who has paid his dues. If not literally done his time. And that after meeting what only the most hardened entrepreneur in any industry would not call a major setback, making the choice to survive and as a result, thrive in the new era of the cannabis industry – internationally.

Rogers is a tall, rangy, GI-Joe handsome and intense man with greying sideburns. Not to mention a supreme distaste for anyone who still resists the cannabis flood.  He is, if one can give a political label to it, “pro cannabis,” and tends to fall within the more libertarian part of the industry. 

Rogers also belongs to the part of the biz that no matter his current incarnations, who worked for legalization in the “old days.” As a result, he is also, like many of his peers, of the mind-set that the present can be characterized as such: the fucking drug cures cancer, is awesome for the right people recreationally too, should be regulated and does not cause insanity much less male titties. You lost the drug war, assholes. Now let me just get on with my business, damnit.

Apart from being no bullshit, however, Rogers is also bottom line focused and has managed, without the direct support of any established “cannabis player” or “power” except a highly dedicated team, to create an intriguing brand all of his own. The vibe at the International Cannabis Business Conference in Berlin as a result, manages to encapsulate the funky edginess of the scene, both presently and even a bit of its bygone days, while being clearly a deals conference par excellence. 

Even from its first year, the conference saw intense commercial activity that looked most like, truth be told, bidding wars at top film festivals rather than national agricultural promotion fairs (which is what they also function as). The former seems a bit hipper (the fashion sense certainly is). Pricing and commodity swaps and contracts aside, the characters and pure international eccentricity is certainly more like the film industry than say your average county or even national produce market. 

Even at an international level. 

And especially given the subject matter at hand. 

Cannabis users or those connected to the industry in any way can increasingly wear their “flower power” paraphernalia, pass out business cards, have LinkedIn profiles, in Europe even bank accounts, and more with pride these days. 

And are everywhere.

That comes in many flavors.

For those of a certain age who grew up literally terrorized by the Drug War, the first day of April 2019 in Berlin at the International Cannabis Business Conference certainly felt again, like a kind of vindication and a marker of a revolution that this time, will not be stopped. 

This time, globally.

Green II: Spreading Like Kudzu is now available